• Valion Bio expects top-line results in early December 2026 from a government-funded animal study of Entolimod for gastrointestinal acute radiation syndrome.
• The study evaluates whether a single dose given 24 hours following radiation exposure improves survival.
• Preclinical safety findings were positive. The National Institute of Allergy and Infectious Diseases is funding the therapeutic study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611110810ACCESSWRNAPR_____1249770) on November 11, 2026, and is solely responsible for the information contained therein.